Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Esperite (ESP) announces that Genoma SA filed appeal to the decision ruled by the Swiss Court

Esperite N.V.
Posted on: 19 May 17

Genoma has filed appeal to the decision of liquidation taken on May 4 th 2017. Genoma considers this decision arbitrary due to the circumstances of the commercial and legal relationship with Premaitha.

Zutphen, The Netherlands, 19 May 2017

Genoma has concluded with Premaitha an agreement in March 15 th 2015 for the supply of the genetic test Iona. The implementation of this contract implied significant investment specifically related to the use of the IONA Kits. Genoma represented 65% of Premaitha's business in 2015/16.

Genoma was forced to discontinue using the Premaitha Iona test some weeks after the serious legal claim against Premaitha's technology by Illumina (Patent Infringement). Premaitha has not been able to demonstrate that the Iona test doesn't infringe Illumina's patents.

Genoma blocked payments to Premaitha, a total of +€900k for several reasons:

  • A considerable amount has been claimed for failure in the supply;
  • Illumina sued Genoma for patent infringement because of the use of Premaitha's Iona;
  • Premaitha never offered valid support for defence despite they were selling a patent infringing product.

The British supplier sent several summons for payment and finally obtained a court decision ruling for the bankruptcy of Genoma officially on May 4 th 2017. The official register was updated on the 9 th of May 2017.

About ESPERITE
ESPERITE Group, listed at Euronext Amsterdam and Paris, is a leading international company in regenerative and predictive medicine established in 2000.

To learn more about ESPERITE Group, or to book an interview with CEO Frederic Amar:  +31 575 548 998  -  ir@esperite.com  or visit the websites at
www.esperite.com  and www.genoma.com .

PR Genoma


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Esperite N.V. via GlobeNewswire
HUG#2106299
GlobeNewswire
globenewswire.com

Last updated on: 20/05/2017

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.